Option Chain

Corcept Therapeutics Inc

CORTNASDAQ · USD

72.77USD+1.14 (+1.60%)

589

Corcept Therapeutics Inc (CORT) Option Chain

Corcept Therapeutics Inc trades at $72.77, up 1.60%, with an IV Rank of 90.08%. This is high versus the past year, and the company carries a market cap of $7,839M in the Biotechnology industry. On the Nov 20, 2026 chain, the at the money $72.50 strike shows calls at $3.10 / $6.10 and puts at $3.80 / $5.30, both carrying about $4.44 of extrinsic value and a roughly 50% probability of expiring out of the money. Volume is heaviest on the $95.00 calls, at 25 contracts, and the $80.00 puts, at 51, as of Nov 5, 2026.

Tracking the CORT option chain helps you see every strike and expiry on Corcept Therapeutics Inc in one view, so you can quickly identify contracts that fit your thesis and your risk. It lays out bids, asks, volume, open interest, and Greeks across calls and puts, giving you the full map of CORT options activity at a glance. Use our scanner to monitor the CORT option chain in real time and filter for the trades that actually meet your criteria.

An option chain is the complete listing of all available option contracts on an underlying, organized by expiration date and strike price. For CORT stock options, the chain shows call and put data side by side, making it easy to compare premiums, assess liquidity, and spot pricing dislocations. Reading it well means looking beyond the last price. Implied volatility by strike, volume to open interest ratios, and bid ask spreads all show where CORT options are being actively traded, and where they are not.

Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with advanced ovarian tumors, as well as for the treatment of cortisol excess.

CALLs									PUTs
Prob. OTM %	Open Interest	Volume	Extrinsic Value	Intrinsic Value	Bid	Ask	Strike	Moneyness %	Bid	Ask	Intrinsic Value	Extrinsic Value	Volume	Open Interest	Prob. OTM %
40.78	0	0	1.93	5.27	5.60	8.80	67.50	-5.77	1.80	3.40	0.00	2.60	0	6	59.22
48.46	23	0	3.03	2.77	4.20	7.40	70.00	-2.28	2.60	4.90	0.00	3.75	2	54	51.54
55.94	5	0	4.33	0.27	3.10	6.10	72.50	+1.21	3.80	5.30	0.00	4.55	0	36	44.06
62.96	293	1	3.55	0.00	2.10	5.00	75.00	+4.70	5.10	6.90	2.23	3.77	8	44	37.04
69.37	9	1	2.78	0.00	1.35	4.20	77.50	+8.19	6.60	8.80	4.73	2.97	1	18	30.63

As of Nov 5, 2026

Prices move. This one stays.Lock in 5 years at a special price and save $2,243. Ending soon.See the Early Bird Black Friday deal →

Stock Statistics

IndustryBiotechnology
SectorHealthcare
IV Rank90.08% High
Market cap (M$)7,839
52 weeks high-43.32%
52 weeks low149.93%
Analyst recommendationBuy
1.86
Target price$142.60
93.76% above the current stock price
Dividend—
Payout ratio0.00%
Earnings date2026-11-03
P/E56.53
Future P/E14.89
EPS (ttm)1.27
EPS growth next 5 years111.06%

As of Nov 5, 2026

Browse all Option Chain tickers